Campbell & Co Investment Adviser’s KalVista Pharmaceuticals KALV Stock Holding History

Campbell & Co Investment Adviser’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-64,249	Closed	-$1.29M	–	1203
2026 Q1	$1.29M	Buy	+64,249	New	+$1.04M	0.07%	421
2024 Q3	–	Sell	-25,522	Closed	-$301K	–	1221
2024 Q2	$301K	Buy	25,522 +15,518	+155%	+$181K	0.03%	828
2024 Q1	$119K	Sell	10,004 -31,361	-76%	-$418K	0.01%	1055
2023 Q4	$507K	Buy	+41,365	New	+$376K	0.05%	705

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Campbell & Co Investment Adviser's KALV Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 64,249 shares — an estimated $1.29M sold.

Campbell & Co Investment Adviser first reported a position in KALV in Q4 2023 and held it in 4 quarters. The position peaked at $1.29M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Campbell & Co Investment Adviser reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 64,249 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.29M.
Campbell & Co Investment Adviser first reported a position in KalVista Pharmaceuticals in Q4 2023 and held it in 4 quarters.
Campbell & Co Investment Adviser's KalVista Pharmaceuticals position peaked at $1.29M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.